Literature DB >> 9202313

Demyelinating antibodies to myelin oligodendrocyte glycoprotein and galactocerebroside induce degradation of myelin basic protein in isolated human myelin.

K K Menon1, S J Piddlesden, C C Bernard.   

Abstract

Although the specificity of multiple sclerosis (MS) brain immunoglobulins (Igs) remains unknown, the incubation of these Igs with human myelin can lead to myelin basic protein (MBP) degradation mediated by neutral proteases. In this study, we demonstrate that monoclonal antibodies (mAbs) specific to myelin components such as the CNS-specific myelin oligodendrocyte glycoprotein (MOG) and galactocerebroside (GalC) are found to induce a significant loss of MBP mediated by neutral proteases in myelin. By contrast, antibodies to periaxonal and structural components of myelin, such as MBP and myelin-associated glycoprotein, are ineffective in inducing such MBP degradation. Among the 11 different anti-MOG mAbs directed to externally located epitopes of MOG, only two were found to induce a significant degradation of MBP, suggesting that antibody-induced MBP degradation is not only antigen specific but also epitope specific. Based on the inhibition of MBP degradation in the presence of EGTA and the analysis of the degradation products obtained following incubation of myelin with mAbs to GalC and MOG (8-18C5), the neutral protease involved in this antibody-induced degradation of MBP could be calcium-activated neutral protease. Taken together, these results suggest that antibodies to GalC and MOG can play a major role in destabilizing myelin through MBP breakdown mediated by neutral proteases and thus have an important role to play in the pathogenesis of MS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9202313     DOI: 10.1046/j.1471-4159.1997.69010214.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  13 in total

Review 1.  The role of B cells in multiple sclerosis: Current and future therapies.

Authors:  Austin Negron; Rachel R Robinson; Olaf Stüve; Thomas G Forsthuber
Journal:  Cell Immunol       Date:  2018-10-21       Impact factor: 4.868

Review 2.  The role of glial-neuronal metabolic cooperation in modulating progression of multiple sclerosis and neuropathic pain.

Authors:  Rachel R Robinson; Alina K Dietz; Asif M Maroof; Reto Asmis; Thomas G Forsthuber
Journal:  Immunotherapy       Date:  2019-02       Impact factor: 4.196

3.  Diminished degradation of myelin basic protein by anti-sulfatide antibody and interferon-gamma in myelin from glia maturation factor-deficient mice.

Authors:  Krishnakumar Menon; Yanghong Wu; Joel Haas; Shailendra K Sahu; Baoli Yang; Asgar Zaheer
Journal:  Neurosci Res       Date:  2007-02-22       Impact factor: 3.304

Review 4.  Sphingolipids in multiple sclerosis.

Authors:  Arundhati Jana; Kalipada Pahan
Journal:  Neuromolecular Med       Date:  2010-07-07       Impact factor: 3.843

5.  Cross-reactivity of anti-galactocerebroside autoantibodies with a Trypanosoma brucei proteolipidic epitope.

Authors:  M Girard; S Bisser; P Buscher; B Bouteille; J L Preud'homme; M O Jauberteau
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

Review 6.  Pathogenic autoantibodies in multiple sclerosis - from a simple idea to a complex concept.

Authors:  Romana Höftberger; Hans Lassmann; Thomas Berger; Markus Reindl
Journal:  Nat Rev Neurol       Date:  2022-08-15       Impact factor: 44.711

Review 7.  Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases.

Authors:  Patrick Peschl; Monika Bradl; Romana Höftberger; Thomas Berger; Markus Reindl
Journal:  Front Immunol       Date:  2017-05-08       Impact factor: 7.561

8.  Effect of Fasudil on remyelination following cuprizone-induced demyelination.

Authors:  Jing Wang; Ruo-Xuan Sui; Qiang Miao; Qing Wang; Li-Juan Song; Jie-Zhong Yu; Yan-Hua Li; Bao-Guo Xiao; Cun-Gen Ma
Journal:  CNS Neurosci Ther       Date:  2019-05-23       Impact factor: 5.243

Review 9.  The immunomodulatory and neuroprotective effects of mesenchymal stem cells (MSCs) in experimental autoimmune encephalomyelitis (EAE): a model of multiple sclerosis (MS).

Authors:  Mohammed A Al Jumah; Mohamed H Abumaree
Journal:  Int J Mol Sci       Date:  2012-07-24       Impact factor: 6.208

10.  Molecular grafting onto a stable framework yields novel cyclic peptides for the treatment of multiple sclerosis.

Authors:  Conan K Wang; Christian W Gruber; Maša Cemazar; Christopher Siatskas; Prascilla Tagore; Natalie Payne; Guizhi Sun; Shunhe Wang; Claude C Bernard; David J Craik
Journal:  ACS Chem Biol       Date:  2013-11-07       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.